Literature DB >> 15215692

HIV-1 gp120 binding to dendritic cell receptors mobilize the virus to the lymph nodes, but the induced IL-4 synthesis by FcepsilonRI+ hematopoietic cells damages the adaptive immunity--a review, hypothesis, and implications.

Yechiel Becker1.   

Abstract

HIV-1 is equipped with the envelope gp160 glycoprotein for interaction with Langerhans cells (LCs) and dendritic cells (DCs), the members of the innate immune system, which confront the virus at the portal of virus entry in the human body. These cells are equipped with receptors by which they bind and endocytose the virus. The gp120 glycoprotein is used for binding to CD4 receptor and CCR5 co-receptor of T helper 2 (Th2) cells and the virions shed gp120 is able to induce FcepsilonRI+ hematopoietic cells to produce IL-4, which inactivate the host adaptive immune response. The properties of gp120s various functional domains are analyzed together with the regulatory viral proteins, which are involved in the damage to T and B cells during HIV-1 replication. The interaction of HIV-1 virions through their gp120 with LCs and DCs at the portal of virus entry will be discussed. A hypothesis will be presented that the understanding of the role of the different functional domains of gp120 in the life cycle of the virus and during AIDS will help in the design of approaches to prevent and abrogate HIV-1 infection and AIDS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215692     DOI: 10.1023/B:VIRU.0000032797.43537.d3

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.198


  93 in total

1.  The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules.

Authors:  T I Prigozy; P A Sieling; D Clemens; P L Stewart; S M Behar; S A Porcelli; M B Brenner; R L Modlin; M Kronenberg
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

2.  Structural basis of the gp120 superantigen-binding site on human immunoglobulins.

Authors:  S Karray; L Juompan; R C Maroun; D Isenberg; G J Silverman; M Zouali
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.

Authors:  R R Garrity; G Rimmelzwaan; A Minassian; W P Tsai; G Lin; J J de Jong; J Goudsmit; P L Nara
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses.

Authors:  L Zheng; X L Huang; Z Fan; L Borowski; C C Wilson; C R Rinaldo
Journal:  AIDS Res Hum Retroviruses       Date:  1999-07-20       Impact factor: 2.205

Review 5.  Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr.

Authors:  Parithosh K Tungaturthi; Bassel E Sawaya; Satya P Singh; Brian Tomkowicz; Velpandi Ayyavoo; Kamel Khalili; Ronald G Collman; Shohreh Amini; Alagarsamy Srinivasan
Journal:  Biomed Pharmacother       Date:  2003-01       Impact factor: 6.529

6.  CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression.

Authors:  Nicoletta Casartelli; Gigliola Di Matteo; Marina Potestà; Paolo Rossi; Margherita Doria
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38.

Authors:  Jin Xie; Jianfei Qian; Siqing Wang; Muta E Freeman; Joshua Epstein; Qing Yi
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

8.  Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models.

Authors:  Che-Chung Tsai; Peter Emau; Yonghou Jiang; Michael B Agy; Robin J Shattock; Ann Schmidt; William R Morton; Kirk R Gustafson; Michael R Boyd
Journal:  AIDS Res Hum Retroviruses       Date:  2004-01       Impact factor: 2.205

9.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).

Authors:  D C Montefiori; K Stewart; J M Ahearn; J Zhou; J Zhou
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  5 in total

1.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

Review 2.  The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals--a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

Review 3.  The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes--a review, hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-04       Impact factor: 2.332

4.  Effects of reticuloendotheliosis virus infection on cytokine production in SPF chickens.

Authors:  Mei Xue; Xingming Shi; Yan Zhao; Hongyu Cui; Shunlei Hu; Xianlan Cui; Yunfeng Wang
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 5.  CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.198

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.